231 related articles for article (PubMed ID: 31312844)
1. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.
Fleischmann R; Genovese MC; Lin Y; St John G; van der Heijde D; Wang S; Gomez-Reino JJ; Maldonado-Cocco JA; Stanislav M; Kivitz AJ; Burmester GR
Rheumatology (Oxford); 2020 Feb; 59(2):292-302. PubMed ID: 31312844
[TBL] [Abstract][Full Text] [Related]
2. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
Kameda H; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham N; Tanaka Y
Mod Rheumatol; 2020 Mar; 30(2):239-248. PubMed ID: 31268376
[No Abstract] [Full Text] [Related]
3. Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors.
Fleischmann R; Genovese MC; Maslova K; Leher H; Praestgaard A; Burmester GR
Rheumatology (Oxford); 2021 Nov; 60(11):4991-5001. PubMed ID: 33871596
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
Burmester GR; Strand V; Kivitz AJ; Hu CC; Wang S; van Hoogstraten H; Klier GL; Fleischmann R
Rheumatology (Oxford); 2023 Oct; 62(10):3268-3279. PubMed ID: 36727470
[TBL] [Abstract][Full Text] [Related]
5. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H
Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR
RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
Genovese MC; Fleischmann R; Kivitz A; Lee EB; van Hoogstraten H; Kimura T; St John G; Mangan EK; Burmester GR
Arthritis Res Ther; 2020 Jun; 22(1):139. PubMed ID: 32522251
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
Burmester GR; Lin Y; Patel R; van Adelsberg J; Mangan EK; Graham NM; van Hoogstraten H; Bauer D; Ignacio Vargas J; Lee EB
Ann Rheum Dis; 2017 May; 76(5):840-847. PubMed ID: 27856432
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; Van Hoogstraten H; Mangan E; Carita P; Huynh TM
RMD Open; 2019; 5(1):e000798. PubMed ID: 30886733
[TBL] [Abstract][Full Text] [Related]
10. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D
Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246
[TBL] [Abstract][Full Text] [Related]
11. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
[TBL] [Abstract][Full Text] [Related]
13. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis.
Lamb YN; Deeks ED
Drugs; 2018 Jun; 78(9):929-940. PubMed ID: 29931592
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
[TBL] [Abstract][Full Text] [Related]
15. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
[TBL] [Abstract][Full Text] [Related]
16. A review of sarilumab for the treatment of rheumatoid arthritis.
Lee EB
Immunotherapy; 2018 Jan; 10(1):57-65. PubMed ID: 29043871
[TBL] [Abstract][Full Text] [Related]
17. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
Genovese MC; van Adelsberg J; Fan C; Graham NMH; van Hoogstraten H; Parrino J; Mangan EK; Spindler A; Huizinga TWJ; van der Heijde D;
Rheumatology (Oxford); 2018 Aug; 57(8):1423-1431. PubMed ID: 29746672
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
[TBL] [Abstract][Full Text] [Related]
19. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y
Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351
[TBL] [Abstract][Full Text] [Related]
20. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR
Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
